{"filing":{"accession_number":"0001140361-26-034854","cik":"0001635088","ticker":"ROIV","company_name":"Roivant Sciences Ltd.","form":"8-K","filing_date":"2026-08-28","report_date":"2026-08-28","primary_document":"ef20081283_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126034854/ef20081283_8k.htm"},"events":[{"id":30356,"run_id":27819,"accession_number":"0001140361-26-034854","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Roivant disclosed FDA approval and commercial launch of LISRAYA (brepocitinib) for dermatomyositis treatment on August 28, 2026. This is a material regulatory milestone and product commercialization event—the company's first approved drug product—but does not fit the specific taxonomy categories. While it is clearly operational/strategic in nature (product approval and launch), it is not a traditional M\u0026A activity, workforce reduction, or material contract. The disclosure centers on regulatory approval achievement and immediate commercial availability, making it a significant operational milestone for the company.","company_name":"Roivant Sciences Ltd.","ticker":"ROIV","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32926,"accession_number":"0001140361-26-034854","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Roivant disclosed FDA approval and commercial launch of LISRAYA (brepocitinib) for dermatomyositis treatment on August 28, 2026. This is a material regulatory milestone and product commercialization event—the company's first approved drug product—but does not fit the specific taxonomy categories. While it is clearly operational/strategic in nature (product approval and launch), it is not a traditional M\u0026A activity, workforce reduction, or material contract. The disclosure centers on regulatory approval achievement and immediate commercial availability, making it a significant operational milestone for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T20:33:32.237277+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32926,"accession_number":"0001140361-26-034854","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Roivant disclosed FDA approval and commercial launch of LISRAYA (brepocitinib) for dermatomyositis treatment on August 28, 2026. This is a material regulatory milestone and product commercialization event—the company's first approved drug product—but does not fit the specific taxonomy categories. While it is clearly operational/strategic in nature (product approval and launch), it is not a traditional M\u0026A activity, workforce reduction, or material contract. The disclosure centers on regulatory approval achievement and immediate commercial availability, making it a significant operational milestone for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T20:33:32.237277+00:00","company_name":"Roivant Sciences Ltd.","ticker":"ROIV","filing_date":"2026-08-28"}]}